NorthStar Medical Radioisotopes, LLC’s Post

Unlocking the Future of Precision Medicine: GMP Radiopharmaceuticals In the rapidly advancing field of nuclear medicine, radiopharmaceuticals play a critical role in diagnosis and treatment. Ensuring their safety, quality, and efficacy starts with strict adherence to Good Manufacturing Practice (GMP) guidelines. GMP-compliant radiopharmaceutical production is key to delivering precise and reliable patient treatments, especially in oncology, cardiology, and neurology. These regulations help mitigate risks associated with contamination, ensure consistent product quality, and maintain the integrity of the supply chain. The combination of rigorous safety protocols with cutting-edge innovation makes GMP radiopharmaceuticals so unique. From small-scale hospital production to global commercial distribution, maintaining GMP standards ensures that every dose administered is effective and safe. This ultimately enhances patient outcomes and promotes confidence in advanced therapeutic modalities. As the healthcare industry continues to evolve, GMP-compliant radiopharmaceuticals are driving the future of personalized medicine, ensuring that every patient receives the right treatment, at the right time, and with the highest level of safety. #Radiopharmaceuticals #GMPCompliance #PrecisionMedicine #NuclearMedicine #PharmaceuticalManufacturing #HealthcareInnovation

Have you already heard about the #upgraded version of our CRP Compact? Watch the new CRP Compact Plus video and discover its latest feature! You can also find an in-depth article here 👉 https://lnkd.in/dV6ffkeU #TemaSinergie #NuclearMedicine #radiopharmaceuticals #MedicalDevices #annex1 #Theranostics

According to our research the global market for medical devices is estimated at US$ 603 billion in the year 2023 and will be growing at a CAGR of 5% during next six years. #NuclearMedicine #HealthcareInnovation #MedicalSoftware #Radiopharmaceuticals #ImageProcessing #PatientCare #MedicalResearch #GlobalMarket #MedicalDevices #HealthcareTechnology

Hi everybody. Perhaps we run into each other and see some of our business partners, followers, and/or users tonight in Toronto. OR see you here tomorrow at the #MetroTorontoConventionCentre meet us at Booth 851 #NEPTIS. Pass by our booth to hear about the #NEPTISxSeed R&D module and discuss with our team and ask Why should the xSeed be in your lab and how can it help you or your team? #SNMMI #radiopharmaceuticals #nuclearmedicine #automatedsynthesismodules with a touch of class.

VALENCIA, Calif. – June 7, 2024 – Nusano, Inc., a physics company transforming the production of medical radioisotopes, today announced industry veteran D. Scott Holbrook as chairman of its board. Holbrook is the co-founder of Invivo Molecular Imaging, and currently serves as the general manager and chief strategy officer for Pharmalogic, a leading contract development and manufacturing organization specializing in novel diagnostic imaging and therapeutic radiopharmaceuticals for the treatment of cancers. He has served on Nusano’s board since September 2022. Holbrook brings over 25 years of experience growing companies in biotech and radiopharmaceuticals to the role. His experience will be critical as Nusano begins commercialization and scale-up of its proprietary medical radioisotope production technologies. “Many highly promising cancer treatments in development are in desperate need of a reliable supply of medical radioisotopes,” said Holbrook. “Nusano’s proprietary technologies are poised to make many of these critical components available and abundant in ways no other production method can. It’s an honor to have this opportunity to lead the board and help advance an exciting new era in radiotherapeutics.” Chris Lowe, CEO of Nusano, commented, “Scott has been an invaluable member of our board and is a passionate advocate for patients. As our production capacity comes online, his strategic insights and experience will help ensure our customer needs are met in a timely and reliable manner.” Radioisotopes are essential components in the active pharmaceutical ingredients (API) of a category of new and emerging cancer therapies, known as radiotherapeutics. Existing supply chains for these treatment-enabling resources are often strained, posing a risk to patient care, clinical trials, and ongoing drug development. Nusano is working to stabilize supply chains and enable innovation by bringing new sources of radioisotopes to commercial markets. The company expects to begin producing and delivering commercial-scale quantities of lutetium-177 in Q1 2025 and actinium-225 in the second half of 2025. Nusano’s first-of-its-kind production facility opens Q1 2025 in West Valley City, Utah. At full scale it will be capable of producing more than 25 radioisotopes of interest to medicine, and the simultaneous production of up to 12 different radioisotopes. In addition to his roles at Nusano and PharmaLogic, Holbrook serves as an adjunct professor in the Department of Radiology at the University of Utah, and on the board of Ratio Therapeutics. He holds a Master of Science in Molecular Imaging and Therapy from Regis College and a Bachelor of Science in Clinical Nuclear Medicine from Wheeling University. #radiopharmaceuticals #radiotherapy #radioisotopes #lutetium #lutetium177 #actinium #actinium225 #fightingcancer

The journey of 18F-FDG synthesis commences at the cyclotron and concludes with its delivery to the patient. #Cyclotron #Radiopharmaceuticals #PatientCare #MedicalTechnology #NuclearMedicine

Dosimetry studies in modern drug development; there is a lot of misunderstanding about its contents and meaning. We would like to clarify this with our comprehensive article on the subject. Some of the questions that we discuss and are important for drug developers: 1. What is the purpose of dosimetry studies? 2. For which compounds is a dosimetry study necessary? 3. What are the preclinical requirements before an in-human dosimetry study can be started? 4. Can a dosimetry study in Phase 0 replace that of Phase 1? 5. How is the dosimetry study conducted for radiopharmaceuticals not suitable for imaging? 6. What dosimetry software is available? 7. What aspects should I take into account when designing my dosimetry trial? All this and more is covered by our experts in the article on our website. https://lnkd.in/e5vtU59J Do you prefer direct contact or tailored information on the dosimetry for your studies? Ask your question in the comments or contact us via our website. #Dosimetry #Radiopharmaceuticals #DrugDevelopment #ClinicalTrials #NuclearMedicine #MolecularImaging

Our recent case study takes an inside look at a midsize #biopharma company developing an innovative #mRNA therapy. To progress its therapy from early development to late-phase #clinicaltrials, the company needed to partner with a #CDMO for support. They turned to Thermo Fisher Scientific’s specialized site in #Ferentino, Italy for #formulationanalysis and #productstabilization assistance. By utilizing a #designofexperiments (DoE) approach, Thermo Fisher was able to help accelerate the company’s time to clinic from three months to three weeks, while also saving 90% of #API compared to a more traditional approach. You can find the full case study and its findings here: https://lnkd.in/eRHYJ5KE

We are thrilled to announce that our VP, Medical Affairs, Kristin Schmiedehausen, MD and all authors of “The Scientific and Clinical Potentials of Imaging Cytotoxic T-Cells Using Zr-89 Crefmirlimab Berdoxam” have been awarded first place in the Educational Exhibits Section of the 2024 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting. The poster provides an overview of the currently available data and potential use cases of our investigational CD8 PET imaging agent, Zr-89 Crefmirlimab Berdoxam. Many thanks to all the collaborators who have worked with us by using our CD8 PET tracer, particularly to those who contributed to the poster.  We are elated at this news and celebrate this achievement. Read the poster here: https://lnkd.in/gpy-G3-V Learn more about CD8 Imaging in Clinical Trials by emailing info@imaginab.com #CD8ImmunoPET #immunooncology #pharma #biotech #SNMMI #radiopharmaceutical #PETCT #nuclearmedicine #theranostics #autoimmuneconditions #radiationoncology #collaborations #theranostics #radiology

💡 With recent industry news showing the continuous and growing interest of Pharma innovators to invest in next gen #RLT and #radiopharmaceuticals , we feel privileged at Alcimed 🙏 to having been working in this innovative space for several years now, where there are still several #uncharted #territories yet to cover and address for patients and professionals. Interested in knowing more about how we have been helping and continue to help you in this space? Check out below, and let me know!